ArticleScientific reports2022
Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Impact of Emphysema on Therapeutic Efficacy and Immune-Related Pneumonitis Risk in NSCLC Patients Receiving ICIs: A Meta-Analysis of Improved Survival but Increased Toxicity.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- The Favorable Short-Term Efficacy of Preexisting COPD for Extensive-Stage Small-Cell Lung Cancer Receiving Immunotherapy.Cancer medicine · 2026Article
- The Goddard score for emphysema predicts the postoperative prognosis in pancreatic cancer.Surgery today · 2026Article
- HighERJ open research · 2026Article
- The safety and effectiveness of immune checkpoint blockade in lung cancer with COPD: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors.Scientific reports · 2025Article
- The Role of Computed Tomography and Artificial Intelligence in Evaluating the Comorbidities of Chronic Obstructive Pulmonary Disease: A One-Stop CT Scanning for Lung Cancer Screening.International journal of chronic obstructive pulmonary disease · 2025Review
- Article
- Review
- COPD and Immune Checkpoint Inhibitors for Cancer: A Literature Review.International journal of chronic obstructive pulmonary disease · 2024Review
- Radiomic biomarkers from chest computed tomography are assistive in immunotherapy response prediction for non-small cell lung cancer.Translational lung cancer research · 2023Article
- Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small-cell lung cancer (NSCLC) might depend on the presence of emphysema, but this association is not established. We aimed to investigate if quantitively and automatically measuring emphysema can predict the effect of ICIs. We retrospectively analyzed 56 patients with NSCLC who underwent immunotherapy at our hospital. We used the Goddard scoring system (GS) to evaluate the severity of emphysema on baseline CT scans using three-dimensional image analysis software. The emphysema group (GS ≥ 1) showed better progression-free survival (PFS) than the non-emphysema group (GS = 0) (6.5 vs. 2.3 months, respectively, p < 0.01). Multivariate analyses revealed that good performance status, GS of ≥ 1, and high expression of PD-L1 were independently associated with better PFS, while smoking status was not. In conclusion, quantitative evaluation of emphysema can be an objective parameter for predicting the therapeutic effects of ICIs in patients with NSCLC. Our findings can be used to generate hypotheses for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.